Skip to main content
HCPCS J9025 · Level II · Part B drug

HCPCS J9025: Injection, azacitidine, 1 mg

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for J9025

Billing unit
1 MG
Azacitidine injection
ASP payment limit
$0.269
October 2026; -32.9% vs July 2026
Practitioner MUE
300
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9025 is the Level II code for Injection, azacitidine, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $0.269 per billing unit, down 32.9% from July 2026. The practitioner MUE allows up to 300 units per date of service (MAI 3). Under OPPS it carries status indicator N. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 20 NDCs to it, sold as Azacitidine, Vidaza by Hikma Pharmaceuticals USA Inc., Sandoz Inc., Northstar RxLLC. No current Billing and Coding Article lists J9025, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9025 at $0.269 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.401 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9025
QuarterPayment limitPerCoinsurance
October 2026$0.2691 MG20%
July 2026$0.4011 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 20 NDCs from 14 labelers to J9025. Report the NDC in the claim's drug segment and bill the number of J9025 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J9025
NDCDrug nameLabelerPackage sizeBilling units / package
00143-9606-01AzacitidineHikma Pharmaceuticals USA Inc.1 × 1100
00781-3491-94AzacitidineSandoz Inc.1 × 1100
16714-0927-01AzacitidineNorthstar RxLLC1 × 1100
16729-0306-10AzacitidineAccord Healthcare Inc1 × 1100
43598-0143-62AzacitidineDr. Reddy's Laboratories Inc.1 × 1100
43598-0305-62AzacitidineDr. Reddy's Laboratories Inc.1 × 1100
43598-0465-62AzacitidineDr. Reddy's Laboratories Inc.1 × 1100
55150-0393-01AzacitidineEugia US LLC1 × 1100
59572-0102-01VidazaCelgene Corporation1 × 1100
60505-6271-01AzacitidineApotex Corp1 × 1100
63323-0771-39AzacitidineFreseniUS Kabi USA, LLC1 × 1100
68001-0313-56AzacitidineBluePoint Laboratories1 × 1100
68001-0527-54AzacitidineBluePoint Laboratories1 × 1100
68001-0620-54AzacitidineBluePoint Laboratories1 × 1100
70121-1237-01AzacitidineAmneal Pharmaceuticals, LLC1 × 1100
71288-0115-30AzacitidineMeitheal Pharmaceuticals Inc.1 × 1100
71288-0153-95AzacitidineMeitheal Pharmaceuticals Inc.1 × 1100
72485-0201-01AzacitidineArmas Pharmaceuticals Inc.1 × 1100
72572-0020-01AzacitidineCivica, Inc.1 × 1100
75907-0225-11AzacitidineDr. Reddy's Laboratories Inc.1 × 1100

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9025. For practitioners the limit is 300 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9025 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services3003 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital3003 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9025 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

J9025 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9025 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, J9025 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Common denials for J9025 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks J9025 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a demo

Frequently asked questions — HCPCS J9025

What does HCPCS code J9025 describe?

J9025 is defined by CMS as "Injection, azacitidine, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for J9025 in October 2026?

The ASP-based payment limit is $0.269 per 1 MG, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $0.401.

How many units of J9025 can be billed per day?

The practitioner Medically Unlikely Edit is 300 units per date of service with adjudication indicator 3 (3 Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J9025?

The October 2026 ASP crosswalk lists 20 NDCs from 14 labelers: Azacitidine (Hikma Pharmaceuticals USA Inc.); Azacitidine (Sandoz Inc.); Azacitidine (Northstar RxLLC); Azacitidine (Accord Healthcare Inc). For example NDC 00143-9606-01 is a 1 package equal to 100 billing units. The crosswalk's billing-units-per-package figure converts each package into J9025 units.

Does J9025 have NCCI bundling edits?

No active practitioner PTP pairs list J9025 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.